Positive SIRONA Study Results Highlight Sirolimus-Coated Balloons as Effective Alternative to Paclitaxel for PAD Treatment

Concept Medical Inc., a global leader in innovative drug delivery technologies, is proud to report positive results from the SIRONA (Head-to-Head...

January 08, 2025 | Wednesday | News
Jacobio Pharma's KRAS G12C Inhibitor Glecirasib Data Published in Nature Medicine, Showcasing Impressive Efficacy in NSCLC

Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets announced that the data from a registrational clinical trial of...

January 07, 2025 | Tuesday | News
Hanx Biopharmaceuticals Doses First Patient in Australia for Phase 1 Clinical Trial of Groundbreaking Cancer Therapy HX044

Hanx Biopharmaceuticals, CO. Ltd, an innovative biotechnology company developing next-generation immunotherapies to address the challenges of unmet medical...

January 03, 2025 | Friday | News
Korean Researchers Pioneer Breakthrough Technique to Transform Fibroblasts into Functional Heart Cells

Korean scientists discover a groundbreaking method to transform ordinary fibroblasts into mature cardiomyocytes Researchers at Korea University have achie...

December 27, 2024 | Friday | News
Hoth Therapeutics Secures Exclusive Patent License from VA and Emory University to Tackle Obesity and Related Diseases

Hoth Therapeutics Enters Exclusive Patent License Agreement with VA and Emory University Hoth Also Expands Its' Intellectual Property to Further Its' Ma...

December 27, 2024 | Friday | News
Fujirebio and Eisai Forge Partnership to Advance Blood-Based Diagnostics for Neurodegenerative Diseases

Fujirebio Holdings, Inc. (President & CEO: Goki Ishikawa; Head Office: Minato-ku, Tokyo), a wholly-owned subsidiary of H.U. Group Holdings, Inc. (Cha...

December 26, 2024 | Thursday | News
Regeneron Announces Positive Phase 2 Results for Factor XI Antibodies REGN7508 and REGN9933 in Preventing Venous Thromboembolism

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced positive Phase 2 results for two novel monoclonal antibodies targeting distinct domains of Fa...

December 20, 2024 | Friday | News
Shuttle Pharmaceuticals and UCSF Collaborate in the U.S. to Advance Theranostic Innovations for Prostate Cancer

Shuttle Pharmaceuticals Holdings, Inc.  a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer ...

December 20, 2024 | Friday | News
Roche Reports Phase IIb PADOVA Study Results for Prasinezumab in Early-Stage Parkinson’s Disease

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced results from the Phase IIb PADOVA study investigating prasinezumab in 586 people with early-stage Parkinson&rs...

December 20, 2024 | Friday | News
Viatris Announces Positive Phase 2b CARE Study Results for Cenerimod in Adults with Moderate-to-Severe Lupus

 Viatris Inc. (NASDAQ: VTRS) announced the publication of Phase 2b CARE study results evaluating the efficacy and safety of ceneri...

December 19, 2024 | Thursday | News
MSD and Hansoh Pharma Enter Exclusive Global License Agreement for Investigational GLP-1 Receptor Agonist HS-10535

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Hansoh Pharma, a Chinese biopharmaceutical company,  announced that they ...

December 19, 2024 | Thursday | News
Eli Lilly’s Kisunla™ (Donanemab) Approved by China’s NMPA for Early Symptomatic Alzheimer’s Disease

Eli Lilly and Company (NYSE: LLY) announced that the National Medical Products Administration (NMPA) in China has approved Kisunla...

December 18, 2024 | Wednesday | News
Sanofi and Teva’s Duvakitug Achieves Key Milestones in Phase 2b Study for Ulcerative Colitis and Crohn’s Disease

Sanofi and Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd., announced that the RELIEVE UCCD phase 2b study met its primary endp...

December 18, 2024 | Wednesday | News
Merck Announces FDA Acceptance of BLA for Clesrovimab (MK-1654), Investigational Monoclonal Antibody for Infant RSV Prevention

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced the U.S. Food and Drug Administration (FDA) has accepted the Biologics L...

December 18, 2024 | Wednesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close